Literature DB >> 10091838

Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy.

P Spirito1, B J Maron.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10091838     DOI： 10.1016/s0735-1097(98)00673-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  10 in total

1.  [Transcoronary ablation of septal hypertrophy (TASH): supersedes it the surgery (myectomy)?].

Authors:  H Kuhn; F Gietzen
Journal:  Herz       Date:  1999-12       Impact factor: 1.443

Review 2.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Alcohol septal ablation: in which patients and why?

Authors:  Paolo Spirito; Jessica Rossi; Barry J Maron
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 4.  Mechanisms and efficacy of LV pre-excitation for patients with heart failure and supra-normal systolic function.

Authors:  D A Kass
Journal:  Heart Fail Rev       Date:  2000-12       Impact factor: 4.214

Review 5.  The diagnosis and treatment of hypertrophic cardiomyopathy.

Authors:  Christian Prinz; Martin Farr; Detlef Hering; Dieter Horstkotte; Lothar Faber
Journal:  Dtsch Arztebl Int       Date:  2011-04-01       Impact factor: 5.594

Review 6.  Hypertrophic cardiomyopathy: management issues in the new millennium.

Authors:  Rajesh Thaman; Sami Firoozi; M S Hamid; William J McKenna
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

7.  Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.

Authors:  Christian Sohns; Samuel Sossalla; Jan D Schmitto; Claudius Jacobshagen; Björn W Raab; Silvia Obenauer; Lars S Maier
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

8.  Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.

Authors:  F H Gietzen; C J Leuner; L Obergassel; C Strunk-Mueller; H Kuhn
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

9.  Percutaneous transluminal septal reduction for hypertrophic obstructive cardiomyopathy: report from an international pilot study.

Authors:  Hope E Buell; Rodney H Stables; Elizabeth R DeLong; Kathy B Shuping; Donna M Killip; Harry M Lever; William J McKenna; David Rubin; Ulrich Sigwart; Morimasa Takayama; Galen S Wagner; Eric L Eisenstein; William H Spencer
Journal:  J Med Syst       Date:  2002-08       Impact factor: 4.460

10.  A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy.

Authors:  Attilio Iacovoni; Paolo Spirito; Caterina Simon; Maria Iascone; Giovanni Di Dedda; Paolo De Filippo; Samuele Pentiricci; Luca Boni; Michele Senni; Antonello Gavazzi; Paolo Ferrazzi
Journal:  Eur Heart J       Date:  2012-04-20       Impact factor: 29.983
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.